Cancer immunotherapy firm CytomX's Q3 revenue falls

CytomX Therapeutics

06/11/2025 22:35

Overview

CytomX Q3 2025 revenue misses analyst expectations, declining significantly year-over-year

Net loss for Q3 2025 was $14.2 mln

Company maintains strong cash position with $143.6 mln in cash and investments

Outlook

Company plans CX-2051 Phase 1 data update in Q1 2026

CytomX to start CX-2051 Phase 1b CRC study with bevacizumab in Q1 2026

Result Drivers

REVENUE DECLINE - Revenue decreased due to completion of Bristol Myers Squibb collaboration obligations and reduced Moderna activities

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$5.96 mln
$11.63 mln (8 Analysts)
Q3 Net Income
-$14.23 mln
Q3 Cash & Investments
$143.60 mln
Q3 Operating Expenses
$21.73 mln
Q3 Operating Income
-$15.77 mln


Press Release: ID:nGNXc8Ys8

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)